SCHEMBL2008926

SCHEMBL2008926

NCCC#CCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL984482 0.95 LOX (0.44)
SCHEMBL17188592 0.88
SCHEMBL460467 0.84
SCHEMBL17599088 0.84
SCHEMBL2203200 0.82 LOX (0.41)
SCHEMBL920251 0.82
SCHEMBL11717223 0.82
SCHEMBL6014588 0.82
SCHEMBL13881513 0.82
SCHEMBL19035464 0.79 LOX (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4396184-B1 DIFUNCTIONAL BIO-BENZOXAZINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF JONES PAUL (GB) 2025-09-17 EP claimed
EP-4565580-A1 ORTHO-SUBSTITUTED DIFUNCTIONAL BIO-BENZOXAZINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF Jones, Paul (GB) 2025-06-11 EP claimed
EP-4396184-A1 DIFUNCTIONAL BIO-BENZOXAZINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF Jones, Paul (GB) 2024-07-10 EP claimed
WO-2024028605-A1 ORTHO-SUBSTITUTED DIFUNCTIONAL BIO-BENZOXAZINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF JONES PAUL (GB) 2024-02-08 WO claimed
WO-2022243655-A1 DIFUNCTIONAL BIO-BENZOXAZINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF JONES PAUL (GB) 2022-11-24 WO claimed
US-20240368148-A1 DIFUNCTIONAL BIO-BENZOXAZINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF JONES PAUL (GB) 2024-11-07 US disclosed
WO-2022243655-A1 DIFUNCTIONAL BIO-BENZOXAZINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF JONES PAUL (GB) 2022-11-24 WO disclosed
US-9873693-B2 Methods of treatment using pyridinonyl PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2018-01-23 US disclosed
US-9873693-B2 Methods of treatment using pyridinonyl PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2018-01-23 US disclosed
US-9161922-B2 Amine oxidase inhibitors CASE WESTERN RESERVE UNIVERSITY (US) 2015-10-20 US disclosed
US-8778977-B2 Pyridinonyl PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2014-07-15 US disclosed
US-8778977-B2 Pyridinonyl PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2014-07-15 US disclosed
EP-2038272-B1 PYRIDINONYL PDK1 INHIBITORS SUNESIS PHARMACEUTICALS INC (US) 2013-09-04 EP disclosed
US-7964633-B2 such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes HOFFMANN-LA ROCHE INC. (US) 2011-06-21 US disclosed
EP-2081889-B1 SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-12-22 EP disclosed
US-20100144730-A1 PYRIDINONYL PDK1 INHIBITORS SUNESIS PHAMACEUTICALS (US) 2010-06-10 US disclosed
EP-2081889-A1 SULFONAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-07-29 EP disclosed
US-20080085928-A1 Sulfonamide derivatives HOFFMANN-LA ROCHE INC. 2008-04-10 US disclosed
WO-2008037628-A1 SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-03 WO disclosed